Canterbury DHB


Anticoagulation during Stem Cell Harvest

General Guidelines for the Management of Patients on Oral Anticoagulation who are Undergoing a Procedure

Risk factors include: TIAs, CVAs, systemic emboli, AF, severe LV systolic dysfunction, recurrent CHF, prior VTE, hypercoagulable conditions.

Pre-Procedural Assessment:

Pre-Procedural Anticoagulation:


Haemostasis Service Standing Orders – June 2011.

CDHB Haematology Service Protocols and Guidelines “The Red Book” – Thrombotic Disorders.

CDHB Management Guidelines For Common Medical Conditions “The Blue Book" (15th Edition, 2013) - Haematology.

‘New Anticoagulant Reversal’ Document -July 2010

PHARMAC Guidelines for Testing and Peri-operative Management of Dabigatran.

About this Canterbury DHB document (86787):

Document Owner:

Haemostasis Service (see Who's Who)

Last Reviewed:

December 2016

Next Review:

December 2018


clexane, dabig

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 86787